Tourmaline Bio (TRML) Competitors

Arrowhead Pharmaceuticals (NASDAQ:ARWR) and Tourmaline Bio (NASDAQ:TRML) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, media sentiment, profitability, valuation, analyst recommendations, institutional ownership, earnings and risk.

Which has higher valuation & earnings, ARWR or TRML?

Tourmaline Bio has lower revenue, but higher earnings than Arrowhead Pharmaceuticals. Arrowhead Pharmaceuticals is trading at a lower price-to-earnings ratio than Tourmaline Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arrowhead Pharmaceuticals	$545.21M	4.36	-$599.49M	-$1.28	-13.45
Tourmaline Bio	N/A	N/A	-$73.21M	-$3.21	-6.54

Do insiders and institutionals hold more shares of ARWR or TRML?

62.6% of Arrowhead Pharmaceuticals shares are held by institutional investors. Comparatively, 91.9% of Tourmaline Bio shares are held by institutional investors. 4.3% of Arrowhead Pharmaceuticals shares are held by insiders. Comparatively, 13.0% of Tourmaline Bio shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Is ARWR or TRML more profitable?

Tourmaline Bio's return on equity of -26.75% beat Arrowhead Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arrowhead Pharmaceuticals	N/A	-40.91%	-11.62%
Tourmaline Bio	N/A	-26.75%	-26.11%

Does the media refer more to ARWR or TRML?

In the previous week, Arrowhead Pharmaceuticals had 14 more articles in the media than Tourmaline Bio. MarketBeat recorded 18 mentions for Arrowhead Pharmaceuticals and 4 mentions for Tourmaline Bio. Tourmaline Bio's average media sentiment score of 0.63 beat Arrowhead Pharmaceuticals' score of 0.05 indicating that Tourmaline Bio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Arrowhead Pharmaceuticals	3 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
Tourmaline Bio	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Do analysts rate ARWR or TRML?

Arrowhead Pharmaceuticals currently has a consensus target price of $43.14, suggesting a potential upside of 150.68%. Tourmaline Bio has a consensus target price of $49.33, suggesting a potential upside of 135.03%. Given Arrowhead Pharmaceuticals' higher probable upside, analysts clearly believe Arrowhead Pharmaceuticals is more favorable than Tourmaline Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arrowhead Pharmaceuticals	0 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.89
Tourmaline Bio	0 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	3.00

Which has more volatility and risk, ARWR or TRML?

Arrowhead Pharmaceuticals has a beta of 0.94, indicating that its share price is 6% less volatile than the S&P 500. Comparatively, Tourmaline Bio has a beta of 2.04, indicating that its share price is 104% more volatile than the S&P 500.

Summary

Tourmaline Bio beats Arrowhead Pharmaceuticals on 9 of the 15 factors compared between the two stocks.